Good day, 360!
Here are some of our top movers today. And don’t forget to join us in Market Masters – the hottest trading room around ?.
PLUS»» Pre-Market Analysis Meets Opportunity = Market Navigator. Live Options 101 class Tues. March 11th @9AM EST. Must be a member to attend ? click here for $400 off now.
Be the best prepared trader on the Street!
FOCUS LIST?
MLYS – Up over 40% in the pre-market after announcing positive topline results from Launch-HTN and Advance-HTN pivotal trials of Lorundrostat for the treatment of uncontrolled or resistant hypertension
TRVI – Up over 30% in pre after announcing positive topline results from the Phase 2a RIVER trial of Haduvio in patients with Refractory Chronic Cough
VRN – Up over 12% in pre after announcing a strategic combination with Whitecap Resources in $15 billion transaction
*sponsored by Blossom Social
? Join the Duolingo for Investing
? Want to learn investing? Check out Blossom, where you can find 50+ hours of Duolingo-style lessons, taught by North America’s largest investing content creators.
?? With a 4.7 rating and ranked an Essential Finance App of 2024 by Apple, Blossom is loved by over 250,000 members.
Join Blossom for free!
HOTLIST?
MLYS – Up over 40% in the pre-market after announcing positive topline results from Launch-HTN and Advance-HTN pivotal trials of Lorundrostat for the treatment of uncontrolled or resistant hypertension
Mineralys Therapeutics Inc. (MLYS) is a clinical-stage biopharmaceutical company that develops medicines to target diseases driven by dysregulated aldosterone in the United States.
In the pre-market this morning, the company announced positive topline data from its pivotal Launch-HTN Phase 3 and pivotal Advance-HTN Phase 2 trials evaluating the efficacy and safety of Lorundrostat for the treatment of uncontrolled hypertension (uHTN) or resistant hypertension (rHTN).
Highlights include:
Launch-HTN met its primary endpoint with lorundrostat 50 mg dose achieving a 16.9 mmHg reduction in systolic blood pressure, and a 9.1 mmHg placebo-adjusted reduction (p-value
Advance-HTN met its primary endpoint with lorundrostat 50 mg dose achieving a highly statistically significant 7.9 mmHg placebo-adjusted reduction assessed by 24hr ABPM at end of treatment, week 12
Lorundrostat demonstrated a favorable safety and tolerability profile in both pivotal trials
Shares of MLYS traded up over 40% in the pre-market in reaction to the news.
The first target for bulls is the pre-market high at $17.34. Beyond that, $18, $20 and the all-time highs at $21.98 come into play.
Below $17.34, targets tot he downside are $15, $14, $13, $12, $11 and then a gap fill at $10.52.
Pre-Market Analysis Meets Opportunity = Market Navigator
Next UP: Options 101w/ Jeff Williams Tues, March 11 @9am EST
Must be a Member to Attend
? Sign up here and take $400 off your membership (expires Tuesday)
TRVI – Up over 30% in the pre-market after announcing positive topline results from the Phase 2a RIVER trial of Haduvio in patients with Refractory Chronic Cough
Trevi Therapeutics Inc. (TRVI) is a clinical-stage biopharmaceutical company that focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.
In the pre-market this morning, the company announced positive topline results from its Phase 2a RIVER trial of Haduvio for the treatment of patients with RCC (N=66).
Haduvio met the primary endpoint with a statistically-significant reduction in the objective 24-hour cough frequency of 67% from baseline and 57% on a placebo-adjusted basis (p
Haduvio showed similar efficacy in patients with moderate or severe cough counts (p
Haduvio is the first and only therapy to show a statistically-significant reduction in chronic cough across both RCC and IPF patients.
Shares of TRVI traded up over 30% in the pre-market in reaction to the news.
The first target for bulls is the pre-market high at $6.11. Beyond that, $7 and $8.50 come into play.
Below $6.11, targets to the downside are $5.60, $5.40, $5.20, $5, $4.75 and then a gap fill at $4.30.
VRN – Up over 12% in pre after announcing a strategic combination with Whitecap Resources in $15 billion transaction
Veren Inc. (VRN) is a Canadian oil and gas company that explores, develops, and produces oil and gas properties in Canada.
In the pre-market this morning, the company announced a strategic combination with Whitecap Resources (TSX: WCP) to create a leading light oil and condensate producer with concentrated assets in the Alberta Montney and Duvernay.
The combined company will be the largest Alberta Montney and Duvernay landholder, a prominent light oil producer in Saskatchewan and will leverage the combined asset base and technical expertise to drive improved profitability and superior returns to shareholders.
Shares of VRN traded up over 12% in the pre-market in reaction to the news.
The $5.40 area acted as support in the pre-market and will be an important level to watch. Above it, targets to the upside are $5.60, $5.80, $6 and then the pre-market high at $6.27. Beyond that, $6.50, $6.75, $7.20 and $7.60 come into play.
Below $5.40, targets to the downside are $5.20, $5 and then a gap fill at $4.91.
MARKET NEWS ?
DISCLAIMER: To more fully understand any Ragingbull.com, LLC (“RagingBull”) subscription, website, application or other service (“Services”), please review our full disclaimer located at https://ragingbull.com/disclaimer
FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. Any RagingBull Service offered is for educational and informational purposes only and should NOT be construed as a securities-related offer or solicitation, or be relied upon as personalized investment advice. RagingBull strongly recommends you consult a licensed or registered professional before making any investment decision.
RESULTS PRESENTED NOT TYPICAL OR VERIFIED. RagingBull Services may contain information regarding the historical trading performance of RagingBull owners or employees, and/or testimonials of non-employees depicting profitability that are believed to be true based on the representations of the persons voluntarily providing the testimonial. However, subscribers’ trading results have NOT been tracked or verified and past performance is not necessarily indicative of future results, and the results presented in this communication are NOT TYPICAL. Actual results will vary widely given a variety of factors such as experience, skill, risk mitigation practices, market dynamics and the amount of capital deployed. Investing in securities is speculative and carries a high degree of risk; you may lose some, all, or possibly more than your original investment.
RAGINGBULL IS NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER. Neither RagingBull nor any of its owners or employees is registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. Employees, owners, and other service providers of https:// ragingbull. com or RagingBull.com LLC are paid in whole or in part by commission based on their sales of Services to subscribers.
RagingBull.com, LLC shall be entitled to recover attorneys’ fees, costs and disbursements. In the event that any suit or action is instituted as a result of doing business with RagingBull. com, LLC and/or its affiliates or if any suit or action is necessary to enforce or interpret these Terms of Service, RagingBull. com, LLC shall be entitled to recover attorneys’ fees, costs and disbursements in addition to any other relief to which it may be entitled.
*Sponsored Content: If you purchase anything through a link in this email other than RagingBull (RB) services, you should assume that we have an affiliate relationship with the company providing the product that you purchase, and that we will be paid in some way. RB is not responsible for any content hosted on affiliate’s sites and it is the affiliate’s responsibility to ensure compliance with applicable laws. We recommend that you do your own independent research before purchasing anything. While we believe in the companies we form affiliate relationships with, please don’t spend any money on these products unless you believe they will help you achieve your goals.
WE MAY HOLD SECURITIES DISCUSSED. RagingBull has not been paid directly or indirectly by the issuer of any security mentioned in the Services except possibly by advertisers in this email. However, Ragingbull.com, LLC, its owners, and its employees may purchase, sell, or hold long or short positions in securities of the companies mentioned in this communication.
#Big #gains #breakthrough #trial #results #mega #mergers